NCT03231943 - GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

September 9, 2018

Study Completion Date

September 9, 2018

Conditions

Infection, Human Immunodeficiency VirusHIV Infections

Interventions

DRUG

GSK3640254

GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.

DRUG

Placebo

Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge